Dosing Regimen for Anti-CD20/Anti-CD3 Bispecific Antibody and Anti-CD79b ADC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing immunotherapies with anti-CD20/anti-CD3 bispecific antibodies like glofitamab for treating B-cell proliferative disorders are limited by adverse effects such as cytokine-driven toxicities, infusion-related reactions, and severe tumor lysis syndrome, necessitating a need for improved dosing strategies to enhance the benefit-risk profile.
Innovation Solution
A dosing regimen involving an anti-CD79b antibody drug conjugate and an anti-CD20/anti-CD3 bispecific antibody, with specific dosing cycles and doses, including a first dosing cycle with initial doses of 2.5 mg and 10 mg, followed by a second cycle with varying doses of 10 mg, 16 mg, or 30 mg, and subsequent cycles with single doses of 10 mg, 16 mg, or 30 mg, administered at specific intervals and durations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-CD20/anti-CD3 bispecific antibody is administered at higher doses to improve therapeutic efficacy, then treatment effectiveness increases, but adverse effects such as cytokine release syndrome and tumor lysis syndrome worsen
Solution Approach 1:
The dosing regimen is segmented into multiple cycles with progressive dose escalation. The first cycle uses lower doses (2.5 mg, then 10 mg), and subsequent cycles increase to higher doses (16 mg, 30 mg). This segmentation allows the immune system to adapt gradually, reducing the severity of adverse effects while achieving therapeutic efficacy over time.
Solution Approach 2:
The treatment employs periodic dosing cycles rather than continuous administration. Each cycle consists of specific doses administered at defined intervals (e.g., days 1, 8, and 15 of cycle 1), allowing recovery periods between doses. This periodic action maintains therapeutic benefit while reducing cumulative toxicity.
2Ease of operation
If dosing regimen is simplified to reduce complexity, then ease of administration improves, but ability to optimize benefit-risk profile deteriorates
Solution Approach 1:
The dosing regimen is dynamic rather than static, allowing adjustment of doses based on patient response and tolerance. The protocol specifies different doses for different cycles (increasing from 2.5 mg to 30 mg), and permits modification based on adverse effects. This dynamic approach maintains ease of administration through clear protocols while optimizing the benefit-risk profile for each patient.
Data Source
AI summary
The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate.